Best SEO title: FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer

The US approval, announced September 18, 2026, covers adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. It adds an oral selective estrogen receptor degrader to abemaciclib, a CDK4/6 inhibitor, for a biomarker-defined population rather than for all patients with ER-positive disease.

The practical change is at the point of endocrine progression. ER and HER2 status alone are not enough to establish eligibility: an ESR1 mutation must be identified using an FDA-approved test. Testing at or after progression matters because ESR1 mutations can be acquired under endocrine selection pressure, particularly during aromatase-inhibitor treatment. A negative result from an archival primary tumor may therefore be less informative than a contemporary assessment.

What supported the approval

The pivotal evidence came from EMBER-3, an international, randomized, open-label phase 3 trial involving 874 patients with ER-positive, HER2-negative advanced breast cancer that had recurred or progressed during or after aromatase-inhibitor therapy. Prior treatment with a CDK4/6 inhibitor was allowed.

Participants were assigned to imlunestrant, standard endocrine therapy chosen by the investigator, or imlunestrant plus abemaciclib. Standard therapy was fulvestrant or exemestane. The trial addressed two related questions: whether imlunestrant improved progression-free survival over standard endocrine therapy, particularly in ESR1-mutated disease, and whether adding abemaciclib improved progression-free survival over imlunestrant alone.

Among patients with ESR1-mutated tumors, median progression-free survival was 5.5 months with imlunestrant alone and 3.8 months with standard endocrine therapy. The hazard ratio for progression or death was 0.62, with a 95% confidence interval of 0.46 to 0.82 and a P value below 0.001. Imlunestrant alone did not produce a statistically significant progression-free survival advantage over standard endocrine therapy in the overall population.

In the trial’s direct combination comparison, median progression-free survival was 9.4 months with imlunestrant plus abemaciclib and 5.5 months with imlunestrant alone. The hazard ratio was 0.57, with a 95% confidence interval of 0.44 to 0.73 and a P value below 0.001. This comparison included patients regardless of ESR1 status; the FDA indication is narrower and requires an ESR1 mutation.

Overall-survival data were not mature enough in the primary report to establish whether the progression-free survival benefit translates into longer survival. The published analysis reported results at the prespecified data cutoff rather than a definitive long-term survival assessment.

Where ESR1 testing enters the pathway

The approval makes ESR1 status a treatment-selection biomarker after endocrine therapy has stopped controlling advanced disease. Testing is not being used to establish the original diagnosis of ER-positive breast cancer. Its purpose is to determine whether a patient with endocrine-resistant disease meets the molecular requirement for imlunestrant plus abemaciclib.

A contemporary blood-based circulating tumor DNA assay can identify ESR1 mutations without a new tissue procedure when sufficient tumor DNA is present. Tumor tissue may also be informative, subject to the test and label requirements. The key issue is timing: because ESR1 mutations may emerge during therapy, testing performed only on tissue collected before endocrine exposure can miss a later resistance alteration.

For a patient whose disease progresses after at least one endocrine-therapy line, the evidence supports obtaining ESR1 results before considering this FDA-approved combination. A previously documented qualifying mutation may establish the biomarker component of eligibility, while an old negative result should be interpreted in light of intervening therapy and the possibility of tumor evolution.

The indication applies to adults and is not limited to women, although breast cancer disproportionately affects women. It also does not extend to HER2-positive disease, early-stage disease, tumors without a confirmed ESR1 mutation, or use before the required endocrine-therapy progression.

Safety and treatment trade-offs

Adding abemaciclib increased toxicity relative to imlunestrant alone. Grade 3 or higher adverse events occurred in 48.6% of patients receiving the combination and 17.1% receiving imlunestrant. In the combination group, commonly reported grade 3 or higher events included neutropenia in 19.8%, anemia in 7.0% and diarrhea in 3.8%.

These findings make the treatment decision broader than mutation status. The evidence supports the combination as an eligible option after endocrine progression, but expected benefit must be considered alongside marrow, gastrointestinal and other established toxicities associated with CDK4/6 inhibition. Monitoring and management should follow the FDA prescribing information rather than be inferred from efficacy results alone.

Important evidence gaps

EMBER-3 was randomized, allowing causal interpretation of its prespecified direct comparisons, but it was open label. Progression-free survival was the principal efficacy endpoint, and mature overall-survival evidence was unavailable in the primary publication. The trial’s combination comparison was against imlunestrant alone, not directly against standard endocrine therapy plus another targeted agent.

The combination result was demonstrated in a broader trial population than the biomarker-restricted FDA indication. Clinicians should therefore distinguish the trial’s all-comer combination comparison from the population legally covered by the approval. The trial was funded by Eli Lilly, the developer of imlunestrant and abemaciclib, making independent follow-up and longer-term outcome reporting important.

Further evidence is needed on optimal sequencing after different CDK4/6 inhibitors, the value of repeating plasma testing after a negative result, efficacy across individual ESR1 variants, quality-of-life outcomes and whether progression-free survival gains lead to longer overall survival.

Questions clinicians ask

When should ESR1 testing be ordered?

The decision point is progression after at least one endocrine-therapy line, before selecting imlunestrant plus abemaciclib. Testing earlier may provide useful information, but an old negative result may not exclude a mutation acquired during subsequent endocrine therapy.

Does every patient with ER-positive, HER2-negative disease qualify?

No. The FDA indication additionally requires advanced or metastatic disease, progression after at least one endocrine-therapy line and a confirmed ESR1 mutation. ER-positive and HER2-negative status without the mutation does not meet the labeled biomarker definition.

Can archival primary-tumor testing rule out eligibility?

Not necessarily. ESR1 mutations can emerge as breast cancer evolves under endocrine pressure, so tissue obtained before that treatment may not reflect the current metastatic clone. A contemporary FDA-approved assay is more relevant when the historical result was negative and progression has since occurred.

Did the trial show an overall-survival benefit?

Not yet. The pivotal report established a progression-free survival benefit for the randomized comparisons, but overall-survival data were immature. Longer follow-up is needed before concluding that the combination extends life rather than delaying progression alone.

References

1. FDA approves imlunestrant combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer — US Food and Drug Administration, 2026 2. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer — The New England Journal of Medicine, 2024 3. A Study of Imlunestrant (LY3484356) in Participants With Breast Cancer (EMBER-3) — ClinicalTrials.gov, 2025